OH2 Injection in Melanoma

To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.

Trial Details

NCT ID
NCT05868707
Phase
PHASE3
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • OH2
  • Salvage chemotherapy or best supportive care
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Over 18 years old, male or female;
  • Stage III or stage IV melanoma that has been definitively diagnosed by pathology and/or cytology and has failed at least second-line standard thera…
  • The overall percentage of subjects with mucosal melanoma will not exceed 22%;
  • Eastern Oncology Consortium (ECOG) physical condition score ECOG 0 \~ 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →